Detailed Study Notes on Blood Transfusion and Organ Transplantation

In 1818, a blood transfusion saved the first human life, marking the beginning of blood transplantation in clinical medicine.
Blood transfusions have become increasingly common, with one in four individuals receiving a transfusion at some point in their lives.
Uses of blood transfusion include:
- Trauma
- Surgery
- Childbirth
- Disease (leading to blood loss)
Components of Blood Transfusion:
- Erythrocytes: Improve respiration and metabolism.
- Plasma: Replaces fluid and prevents bleeding.
- Platelets: Facilitate clotting to prevent excessive bleeding.
Four key properties of blood that facilitate its transplantation:
1. Can be donated by healthy individuals without compromising their own health.
2. The procedure of blood transfusion is simple and inexpensive, involving only intravenous infusion of a liquid graft.
3. Only requires short-term function of transfused blood components, as opposed to organs that must function for a lifetime (e.g., kidneys).
4. Erythrocytes in blood do not express HLA class I or II antigens, major barriers to organ and tissue transplantation. Leukocytes, which do express HLA antigens, are often removed before transfusion.

Successful blood transfusion relies on compatibility for the ABO blood group antigens.
ABO Antigens:
- Determined by carbohydrates on glycolipids and band 3 glycoprotein on erythrocyte surfaces.
- Antigens A and B can stimulate immune reactions in those without respective antigens, unlike the O antigen.
- O individuals produce antibodies against A and B antigens (specifically IgG).
Hypersensitivity Mechanism:
- Type O individuals transfused with A or B blood can experience immune reactions resulting in lysis of transfused erythrocytes due to binding of anti-A or anti-B antibodies, leading to severe complications such as renal failure or death.
Alloantigens and Alloantibodies:
- Alloantigens: Antigens that differ among genetically unrelated individuals within a species (i.e., ABO antigens).
- Alloantibodies: Antibodies generated in response to those alloantigens.
Blood Types and Combinations:
- Four blood types: O, A, B, and AB.
- This leads to 16 combinations of donor-recipient pairs, of which 9 are compatible and 7 are not.
- Rh System: RhD incompatibility further complicates transfusions, as RhD– individuals receiving RhD+ blood may develop specific anti-RhD antibodies, risking future transfusions and pregnancies.
Crossmatch Test:
- Before transfusions, compatibility is evaluated to ensure safe blood type matching.
- Additional blood group antigen systems exist, but ABO and RhD matching typically suffices.

ABO Antigens in Organ Transplants:
- ABO antigens are also found on the endothelial cells of blood vessels, which can lead to rapid organ rejection (hyperacute rejection) if mismatched.
- Example: Type O recipient receiving a kidney from a type A donor experiences anti-A antibody binding to the graft's blood vessels, resulting in graft failure.
Prevention of Hyperacute Rejection:
- Typing and cross-matching for ABO antigens reduces the risk of fatal rejection.
- Additionally, recipients must be screened for pre-existing anti-HLA antibodies from previous transfusions or pregnancies to avoid hyperacute rejection.

Pregnancy can stimulate the formation of anti-HLA antibodies in mothers due to the introduction of fetal HLA antigens into maternal circulation during childbirth.
Previous interactions with blood transfusions can similarly lead to sensitization against HLA antigens, complicating future transplantation options.
Many patients develop antibodies after multiple blood transfusions, leading to high panel reactive antibody (PRA) percentages, which complicate finding compatible donors.

Rejection responses are primarily driven by alloreactive T cells in clinical transplantation.
Acute rejection occurs when the recipient’s T cells attack the transplanted tissue or organ, particularly after solid organ transplants.
Hematopoietic stem cell transplants can result in graft-versus-host disease (GVHD), where donor T cells attack the recipient’s tissues, causing systemic damage.

Renal transplant recipients often experience prior inflammation due to chronic kidney issues.
The inflammatory state exacerbates following transplantation, leading to heightened immune responses against the transplanted organ.
Using living donors can mitigate inflammation and improve transplant outcomes due to reduced ischemic damage.

Mixed Lymphocyte Reaction:
- An experimental model to test how T cells from a patient respond to a donor's HLA antigens.
Importance of HLA Matching:
- Graft survival is directly tied to the degree of HLA matching between donor and recipient, and powerful immunosuppressants are often needed.

The acute rejection response is mediated by direct allorecognition, wherein recipient T cells recognize and respond to mismatched donor HLA.
Direct Pathway of Recognition:
- Recipient T cells activate and proliferate in response to donor HLA-class I and II, leading to acute rejection similar to type IV hypersensitivity reactions.
Immunosuppressive drugs are critical for preventing acute rejection occurrences.

Chronic rejection manifests months after transplant, characterized by vascular damage due to antibody formation against donor HLA antigens.
The immune complexes cause inflammation and eventual loss of function in the graft, posing long-term risks.

HLA-A, -B, -C, and -DR allotypes are critical for successful matching.
The better the match, the better the transplant outcomes, as evidenced by statistical analyses.

Diverse immunosuppressive strategies are essential due to limited organ supply and high demand.
Immunosuppressive drugs can have adverse side effects, including increased risk of infection and malignancies.

Antibodies and drugs given to deplete leukocytes pre-surgery prevent swift immune reactions against the graft.
Rabbit Antithymocyte Globulin (rATG) and Alemtuzumab: Reduce immune reactivity by targeting surface proteins on lymphocytes.

Cyclosporin and Tacrolimus inhibit T-cell activation by preventing signaling needed for T-cell proliferation in response to alloantigens.
Blocking these pathways significantly enhances graft survival rates post-transplantation.

Anti-CD25 monoclonal antibodies prevent T-cell activation by blocking IL-2 receptor interactions that are necessary for T-cell proliferation and activity.
Rapamycin selectively inhibits late-stage signaling in T-cells, promoting suppressive effects in renal transplant contexts.

Azathioprine and Mycophenolate Mofetil: Prevent T-cell proliferation by targeting nucleotide biosynthesis, leading to widespread effects including anemia and gastrointestinal distress.
Cyclophosphamide: Used in cancer and transplant therapy; inhibits rapidly dividing cells but poses severe toxicity risks.